Shingles vaccine may slow biological aging and reduce inflammation: A groundbreaking study reveals potential long-term benefits
A shingles vaccine may offer more than just protection against a painful rash. Recent research from the USC Leonard Davis School of Gerontology suggests it could also contribute to slower biological aging in older adults. This finding highlights the potential for vaccines to play a broader role in promoting healthy aging.
The study, published in the Journals of Gerontology, analyzed data from the U.S. Health and Retirement Study, focusing on over 3,800 adults aged 70 and above in 2016. After accounting for health and demographic factors, vaccinated individuals demonstrated slower overall biological aging compared to those who were not vaccinated.
Shingles, a painful rash caused by the reactivation of the chickenpox virus, is a concern for anyone who has had chickenpox. The risk increases significantly after age 50 and is higher in immunocompromised individuals. Vaccination not only reduces the likelihood of shingles but also lowers the risk of postherpetic neuralgia, a long-term nerve pain that can persist after the rash clears.
The study's lead researcher, Jung Ki Kim, noted that earlier studies have linked adult vaccines, including shingles and influenza shots, to lower risks of dementia and other neurodegenerative diseases. This adds to the growing evidence that vaccines may have broader health benefits beyond infection prevention.
Biological aging, distinct from chronological age, refers to the body's system functionality. Two 65-year-olds can have vastly different biological profiles. The study evaluated seven markers of biological aging: inflammation, innate immunity, adaptive immunity, cardiovascular hemodynamics, neurodegeneration, epigenetic aging, and transcriptomic aging. These markers were combined into an overall biological aging score.
The findings revealed that vaccinated participants had lower inflammation levels, slower epigenetic and transcriptomic aging, and better overall biological aging scores. This clarifies the potential impact of immune health on the aging process.
Low-grade, long-lasting inflammation is linked to various aging-related conditions, including heart disease, frailty, and cognitive decline. Researchers call this persistent inflammation 'inflammaging'. The vaccine's potential to reduce this background inflammation by preventing virus reactivation may support healthier aging.
Interestingly, the benefits of vaccination persisted for several years. Participants who were vaccinated four or more years before providing a blood sample still showed slower epigenetic, transcriptomic, and overall biological aging compared to unvaccinated individuals. This suggests the potential for long-term effects.
The study's co-author, Eileen Crimmins, emphasized the significance of these findings, indicating that shingles vaccination influences key aspects of the aging process. While further research is needed to confirm and expand these results, the study contributes to the growing evidence that vaccines may be integral to healthy aging strategies beyond preventing acute illness.
